During the third and fourth Charles Blackley symposia in Notingham, in 1978 and 1981 , we presented our experiences of this type of therapy. Since triamcinolone acetonide was rarely used in the United Kingdom, however, our communications did not arouse much interest.
The principles included in Dr Willey's report seem open to question, as does his interpretation. This would seem to derive from his assumption that the weight of triamcinolone acetonide in dosage is equivalent to that of triamcinolone. This is, however, not the case. According to information made available to investigators by ER Squibb Ltd triamcinolone acetonide (in rats) is 10 times more potent in anti-inflammatory and nine times more potent in neoglucogenetic properties than triamcinolone alcohol and prednisolone. To achieve an equivalent dosage of triamcinolone and prednisolone the weight of triamcinolone_ acetonide should be multiplied by 12. Therefore Dr Willey's statement to the effect that 80 mg of triamcinolone acetonide every 28 days is equivalent to 3-43 mg of prednisolone daily is incorrect. In fact, it is a very high dose, equivalent to over 35 mg of prednisolone daily.
In long term therapy we never exceed 1-7 mg of triamcinolone acetonide (80 mg every six weeks) as a calculated daily dosage, and when the need to exceed this dosage arises this means that the treatment must be changed and another type of steroidal drug applied, because 1-7 mg of triamcinolone acetonide daily is, in our opinion, equivalent to 16 mg of triamcinolone in tablet form.
In long term treatment of the majority of steroid dependent patients, we usually achieve good results with 1-0-1-2 mg of triamcinolone acetonide daily (equivalent of 2-3 tablets of triamcinolone). We never give injections of triamcinolone acetonide at regular intervals, but give them only when a patient exceeds the safe dosage of bronchodilators. This type of treatment excludes an unnecessary excess of glucocorticoid administration. When Dr Willey's therapy is analysed it is not surprising that 30% of the patients revealed signs of myopathy. We observed only two patients who developed myopathy among over 300 patients treated with triamcinolone acetonide over a period of two years. These two patients had been taking 80 mg of triamcinolone acetonide every three weeks withoutmedical supervision. Nevertheless, our study on a group of 20 patients, treated with triamcinolone acetonide forron an average of 6-4 years and without clinical signs of myopathy, confirmed that in 15 of them an abnormal electromyographic tracing could be observed.
Four out of 12 of Dr Willey's patients showed menstrual disturbances. We do not know how many of the female patients were still menstruating (the ages of the whole group were given as 15-76 years). This side effect ought to have been discussed in terms of the percentage of females of reproductive age.
In our study menstrual disturbances were quite frequent, so we decided that women of reproductive age were not to be treated with triamcinolone acetonide.
Easy bruising was the most frequent side effect of tnamcinolone acetonide treatment, particularly in the elderly (we call this "kenalog hands"). This is very often the reason for taking patients off the triamcinolone acetonide regimen. It is extraordinary that this side effect was not observed in Dr Willey's study.
The authors conclude that better results can be achieved with tnamcinolone acetonide than with prednisolone. This is true, but with a much higher equivalent dosage.
I fully agree that even with a high triamcinolone acetonide dose adrenal cortex suppression was less pronounced. Our "twin studies" (4) 
